RecruitingNCT07063901

Multimodal Deep Learning for Predicting Treatment Response to Neoadjuvant Chemoimmunotherapy in Esophageal Cancer

Sponsor

Central South University

Enrollment

200 participants

Start Date

Jun 1, 2025

Study Type

OBSERVATIONAL

Conditions

Esophagus Cancer

Summary

This observational study aims to investigate a clinical cohort of patients with locally advanced esophageal cancer undergoing neoadjuvant chemoimmunotherapy. By integrating multimodal clinical data-including demographic characteristics, medical history, imaging studies, pathological findings, and laboratory tests-and employing deep learning algorithms, the study seeks to develop predictive models for the early and accurate assessment of treatment response prior to surgery. Specifically, this study focuses on addressing the following key scientific questions: 1. Can multimodal clinical data be used to construct an accurate model for predicting pathological complete response (pCR) following neoadjuvant therapy? 2. Can deep learning models enable early identification of patients with suboptimal response to neoadjuvant therapy, defined as stable disease (SD) or progressive disease (PD), before surgery?

Eligibility

Plain Language Summary

Simplified for easier understanding

This study uses deep learning (AI) to analyze medical images and clinical data before and after pre-surgery treatment in esophageal cancer, aiming to predict which patients respond well enough to surgery and help personalize care decisions. **You may be eligible if...** - You have esophageal cancer confirmed by biopsy - You received or are planned to receive neoadjuvant chemoimmunotherapy (chemotherapy plus immunotherapy given before surgery) - You have complete imaging data available before and after this pre-surgery treatment - Your doctors have recommended you for surgery following multidisciplinary review **You may NOT be eligible if...** - You refused surgery despite being deemed eligible by your surgical team - Your imaging data is incomplete or poor quality - You have another active cancer in addition to esophageal cancer - Your clinical data is incomplete Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Locations(1)

The Second Xiangya Hospital of Central South University

Changsha, Hunan, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07063901

Related Trials

CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal Cancer

NCT051871821 location

The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study

NCT0407530518 locations